Insights Into Maintenance Therapy in Acute Myeloid Leukemia (AML) 2024

Perspectives on frontline and maintenance therapy for AML and factors that guide treatment choices

Florida – February 9, 2024
Purchase Report

Faculty Chair

Tapan Kadia, MD

MD Anderson Cancer Center, Houston, TX, USA

More Information

  • Tampa, FL
  • Florida

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A moderated roundtable discussion focusing on the treatment of AML
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained: venetoclax, gilteritinib, CC-486, azacitidine, cytarabine and daunorubicin (ie, 7+3), CPX-351, ivosidenib, gemtuzumab ozogamicin, midostaurin, and sorafenib

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in Insights Into Maintenance Therapy in Acute Myeloid Leukemia (AML) 2024.

Complete the form below to receive additional information.